Does GD2 synthase (GD2S) detect cancer stem cells in blood samples of breast carcinomas?

IF 2 4区 医学 Q3 MEDICINE, RESEARCH & EXPERIMENTAL
Journal of applied biomedicine Pub Date : 2021-12-01 Epub Date: 2021-09-16 DOI:10.32725/jab.2021.019
Maryam Mansoori, Isa Abdi Rad, Alireza Mirzaei, Kevin J Tam, Seyed Mohsen Hosseini, Rahim Mahmodlu, Fatemeh Mansouri, Leili Saeednejad Zanjani, Zahra Madjd
{"title":"Does GD2 synthase (GD2S) detect cancer stem cells in blood samples of breast carcinomas?","authors":"Maryam Mansoori,&nbsp;Isa Abdi Rad,&nbsp;Alireza Mirzaei,&nbsp;Kevin J Tam,&nbsp;Seyed Mohsen Hosseini,&nbsp;Rahim Mahmodlu,&nbsp;Fatemeh Mansouri,&nbsp;Leili Saeednejad Zanjani,&nbsp;Zahra Madjd","doi":"10.32725/jab.2021.019","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Cancer stem cells (CSCs) are a theorized subset of cells within the tumor that is thought to drive disease recurrence and metastatic spread. The aim of this study is to investigate mRNA and protein levels of ganglioside GD2 synthase (GD2S), in breast cancer (BC) patients.</p><p><strong>Methods: </strong>65 PBMCs of preoperative BC patients without chemotherapy were compared to PBMCs after chemotherapy and controls.</p><p><strong>Results: </strong>GD2S were significantly higher in BC patients after chemotherapy compared to pre-chemotherapy at both mRNA and protein. GD2S was higher in pre-chemotherapy blood samples compared to control samples.</p><p><strong>Conclusions: </strong>Higher expression of GD2S in BC samples compared to healthy control indicates the potential utility of GD2S as a marker of malignancy.</p>","PeriodicalId":14912,"journal":{"name":"Journal of applied biomedicine","volume":"19 4","pages":"181-189"},"PeriodicalIF":2.0000,"publicationDate":"2021-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of applied biomedicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.32725/jab.2021.019","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2021/9/16 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: Cancer stem cells (CSCs) are a theorized subset of cells within the tumor that is thought to drive disease recurrence and metastatic spread. The aim of this study is to investigate mRNA and protein levels of ganglioside GD2 synthase (GD2S), in breast cancer (BC) patients.

Methods: 65 PBMCs of preoperative BC patients without chemotherapy were compared to PBMCs after chemotherapy and controls.

Results: GD2S were significantly higher in BC patients after chemotherapy compared to pre-chemotherapy at both mRNA and protein. GD2S was higher in pre-chemotherapy blood samples compared to control samples.

Conclusions: Higher expression of GD2S in BC samples compared to healthy control indicates the potential utility of GD2S as a marker of malignancy.

GD2合成酶(GD2S)能否检测乳腺癌血液样本中的肿瘤干细胞?
癌症干细胞(CSCs)是肿瘤细胞的一个理论子集,被认为是驱动疾病复发和转移扩散的细胞。本研究的目的是探讨乳腺癌(BC)患者神经节苷脂GD2合成酶(GD2S)的mRNA和蛋白水平。方法:将65例术前未化疗的BC患者的pbmc与化疗后及对照组的pbmc进行比较。结果:化疗后BC患者GD2S mRNA和蛋白水平均明显高于化疗前。化疗前血液样本的GD2S高于对照样本。结论:与健康对照相比,BC样本中GD2S的表达更高,表明GD2S可能作为恶性肿瘤的标志物。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Journal of applied biomedicine
Journal of applied biomedicine PHARMACOLOGY & PHARMACY-
CiteScore
2.40
自引率
7.70%
发文量
13
审稿时长
>12 weeks
期刊介绍: Journal of Applied Biomedicine promotes translation of basic biomedical research into clinical investigation, conversion of clinical evidence into practice in all medical fields, and publication of new ideas for conquering human health problems across disciplines. Providing a unique perspective, this international journal publishes peer-reviewed original papers and reviews offering a sensible transfer of basic research to applied clinical medicine. Journal of Applied Biomedicine covers the latest developments in various fields of biomedicine with special attention to cardiology and cardiovascular diseases, genetics, immunology, environmental health, toxicology, neurology and oncology as well as multidisciplinary studies. The views of experts on current advances in nanotechnology and molecular/cell biology will be also considered for publication as long as they have a direct clinical impact on human health. The journal does not accept basic science research or research without significant clinical implications. Manuscripts with innovative ideas and approaches that bridge different fields and show clear perspectives for clinical applications are considered with top priority.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信